Article,
Anticoagulation in atrial fibrillation. A large real-world update
Affiliations
- [1] Univ Turin, Dept Med Sci, Sect Geriatr, AOU Citta Salute & Sci, Turin, Italy [NORA names: Italy; Europe, EU; OECD];
- [2] Univ Turin, Dept Med Sci, Sect Geriatr, AOU Citta Salute & Sci, Turin, Italy [NORA names: Italy; Europe, EU; OECD];
- [3] Univ Florence, Dept Expt & Clin Med, Largo G Brambilla 3, I-50134 Florence, Italy [NORA names: Italy; Europe, EU; OECD];
- [4] CliCon Soc Benefit Srl, Hlth Econ & Outcome Res, Bologna, Italy [NORA names: Italy; Europe, EU; OECD];
- [5] Osped S Maria Misericordia, Fdn Umbra Cuore & Ipertens ONLUS & Struttura Comp, Perugia, Italy [NORA names: Italy; Europe, EU; OECD];
(... more)
Abstract
Conclusions: Beyond confirming the association with a better net clinical benefit of DOACs over VKAs, our findings substantiate the large proportion of NVAF patients still inappropriately anticoagulated, thereby reinforcing the need for educational programs.
Keywords
Aspirin,
Atrial fibrillation,
Direct oral anticoagulants,
Real-world,
Vitamin K antagonists